Time Folio Asset Management
VC Fund
Time Folio Asset Management is a VC fund focused on Biotechnology and Pharmaceutical. Time Folio Asset Management
- Total investments:
- 16
- Last investment:
- Lead investor:
- 6%
Last updated:
For AI agents: llms.txt
Industries Time Folio Asset Management invests in
Stages Time Folio Asset Management invests in
Countries Time Folio Asset Management invests in
Round sizes
Round size
- Series A
- $5M–$26M
- Series B
- $13M–$28M
- Series C
- $12M–$33M
Investment Focus
Industry
- Biotechnology 8 (50%)
- Pharmaceutical 4 (25%)
- Health Care 3 (19%)
- Biopharma 2 (13%)
- Life Science 2 (13%)
Stage
- Series B 8 (50%)
- Series C 4 (25%)
- Series A 3 (19%)
- Funding Round 1 (6%)
Country
- South Korea 11 (69%)
- United States 3 (19%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Point2 Technology
|
Point2 Technology develops a dielectric waveguide for high speed interconnect for both datacenter applications. The company is a provider of interconnect technology solutions that delivers ultra-low power, low-latency, point-to-point interconnect and range enhancement SoC solutions specifically designed to fulfill the bandwidth needs of hyperscaleAI/ML datacenters and 5G infrastructure. | $22M / Series B / May 25, 2022 | |
Monday OFF
|
Monday OFF is a mobile game developer and publisher located in South Korea. | $5M / Series A / May 12, 2022 | |
IVIM Technology
|
IVIM Technology offers live cell intravital imaging, repetitive intravital imaging, drug efficacy, and delivery monitoring solutions. | $12.1M / Series C / Apr 21, 2022 | |
Animal Industry Data Korea
|
Animal Industry Data Korea is a livestock healthcare solution provider company. | $16.9M / Series B / Nov 03, 2021 | |
StradVision
|
StradVision offers an embedded perception algorithm designed for advanced driver assistance systems and applications in autonomous vehicles. Utilizing its production-ready ADAS software IP platform, which employs camera-based perception AI or LiDAR, StradVision is committed to its roadmap towards achieving autonomous driving. The machine learningalgorithm developed by StradVision has attained the top performance in prestigious technological evaluations, including scene text detection in both English and Chinese, as well as pedestrian detection. StradVision's computer vision algorithm is both precise and rapid, operating seamlessly on embedded and IoT devices. | $33.4M / Series C / Oct 09, 2021 | |
BreezeBio
|
GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s proprietary technology, NanoGalaxy™ platform solves current delivery challenges by systematically screening its nanoparticle library and providing safer and efficient delivery to target tissues. Thecompany's tool makes therapeutic gene editing possible and is easier to use, faster and more accurate than previous gene-editing techniques and thus has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases. | $26M / Series A / Sep 23, 2021 | |
Tomocube
|
Tomocube’s is dedicated to delivering products that can enhance biological and medical research via novel optical solutions that can assist Tomocube in understanding, diagnosing, and treating human diseases.Current optical microscopes only provide users with a 2D view of their sample. To get a 3D view, users must use expensive and invasiveelectron or confocal microscopes, which require extensive pre-preparation of samples and are not amenable to dynamic samples such as live cells. Their platform enables researchers to measure nanoscale, real-time, dynamic images of individual living cells without the need for sample preparation. | $18M / Series C / Sep 23, 2021 | |
SCAI Therapeutics
|
SCAI Therapeutics is a drug delivery platform bio-venture company for pharmaceutical industry. | $27.5M / Series B / Jul 15, 2021 | |
DEEPX
|
DEEPX is a Korean AI hardware system solution company. | $17.7M / Series B / May 20, 2021 | |
AbTis
|
AbTis is a biotechnology company that provides antibody-drug conjugation technology and solubilization. | $13.5M / Series B / Feb 02, 2021 | |
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Time Folio Asset Management invest in?
Time Folio Asset Management invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series B and Series C stage. Most of the 16 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Time Folio Asset Management's check size?
Time Folio Asset Management typically joins rounds of $5M–$26M at Series A, $13M–$28M at Series B and $12M–$33M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Time Folio Asset Management participates in.
When did Time Folio Asset Management last invest?
The most recent investment recorded for Time Folio Asset Management closed in May 2022. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
